The Childhood Brain Tumor Foundation, Maryland was pleased to be a SILVER sponsor for the ISPNO 2018 and provide sponsorship support for the Nurses Symposium. ISPNO 2018 held a Family Day June 29th. Family Day is supported by several organizations. This day of programs was created “by families, for families” and is divided into subject …
Jean-Francois Rual, Ph.D. University of Michigan Progress Update from 1st year: 8/1/2014-7/30/2016 Millions of cells are formed every day in the developing brain of children. Medulloblastoma, the most common and ag-gressive form of pediatric brain tumor, occurs when the proliferation of cells in the cerebellum becomes uncontrolled, The Notch path-way is a key mechanism that …
Kevin Bielamowicz, M.D., Arkansas Research Institute 2016, second year Poor outcomes for children with high grade glioma (HGG) warrant novel therapeutic strategies, and redirecting immune cells can achieve this aim while minimizing side effects to normal cells. Using mathematical modeling in a group of brain tumor samples, we discovered substantial variation between individual cells within …
Hai-Ri Song, M.D., Assistant Professor, Department of Neurosurgery/Neurology, New York University School of Medicine one year, 2016 In spite of dramatic advances in the cure rate for most childhood malignancies, the prognosis for children with brain tumors is exceedingly poor. The urgent need for novel therapy is underscored by the fact that brain tumors are …
The 17th International Symposium on Pediatric-Oncology was held in Liverpool, ENGLAND, June 12-15, 2016. The Childhood Brain Tumor Foundation was pleased to be a Silver Sponsor of the comprehensive meeting, sponsoring a couple of sessions. The event had a record turnout. The summer newsletter will feature a session from Family Day, held on June 11, …
2016 Summary Principal investigators: Dimitris Placantonakis and Jayeeta Basu, NYU School of Medicine Glioblastoma (GBM) is a deadly brain tumor affecting children and adults. The biology of GBM is not well understood and, as a consequence, treatments are limited and ineffective. GBM grows rapidly and invades normal brain tissue, but never metastasizes to other organs. …
Claudia Petritsch, Ph.D. Funded 2015, second year BRAF Mutation effects on malignant astrocytoma development and therapy responses. Abstract: CD133+ subpopulations of cells in glioblastoma (GBM) show in vivo resistance to treatment with radiation and temozolomide, and are thought to contribute to therapy evasion and tumor recurrence. Frequent hyperactivation of the MAPK pathway in GBM has …
Rheal Towner, Ph.D., Oklahoma Medical Research Foundation Progress Update from 2nd year: 9/2012-8/2014 The Childhood Brain Tumor Foundation funded project, Novel Agent for Pediatric Glioblastomas (pGBMs), headed by Dr. Rheal Towner at the Oklahoma Medical Research Foundation, is assessing a novel agent, Oklahoma Nitrone 007 (OKN-007), in pre-clinical mouse models for pediatric glioblastomas (pGBs). Patient-derived …
Marius Wernig, M.D., Ph.D. Stanford University School of Medicine The lysine 27 to methionine substitution in histone variant H3.3 (H3.3-K27M) is the most common mutation in pediatric high grade gliomas. Recent studies have demonstrated that this mutation leads to a global reduction of H3K27 trimethylation in a dominant manner by sequestering an enzymatic subunit of …